RapidAI has received U.S. Food and Drug Administration (FDA) clearance for Rapid Aortic, a deep clinical AI solution designed to transform the assessment and long-term management of aortic disease. The new product enables radiologists, surgeons, and clinicians to quickly and accurately evaluate the aorta using advanced AI-driven tools, reducing cognitive load and improving workflow efficiency. Rapid Aortic, part of the Rapid Aortic product suite, leverages the company’s Rapid Enterprise™ Platform to deliver comprehensive analysis of CT scans that include the aorta—covering the aortic arch in the chest to the iliac arteries in the pelvis. The system automatically generates guideline-based measurements, including six zonal maximums and eighteen landmark metrics, with consistent, reproducible results free from inter-reader variability. It also produces automated 3D reconstructions of the entire aorta and supports longitudinal tracking by comparing current scans with prior studies, enabling early detection of changes that may require urgent intervention. The solution integrates seamlessly into existing clinical workflows through Rapid Edge Cloud, a hybrid cloud-based IT platform with on-prem capabilities ensuring uninterrupted service during outages. Rapid Aortic is fully embedded in Rapid Navigator Pro, the company’s next-generation radiology solution, as well as its mobile and web applications. This integration allows clinicians to access, compare, and act on findings directly within PACS, EHR, and reporting systems without disrupting their daily routines. Designed to go beyond basic triage, Rapid Aortic delivers actionable, clinically adaptive intelligence that supports acute treatment decisions, transfer planning, and long-term surveillance. Advanced visualizations and lab-quality imaging enhance pre-procedure planning for vascular and cardiothoracic surgeons. Personalized notifications help streamline follow-up care and reduce the risk of missed appointments or progression. Dr. Trissa Babrowski, Vascular Surgeon at the University of Chicago, praised the technology, stating it empowers physicians to efficiently identify, confidently assess, and diligently monitor aortic patients with instant access to standardized measurements and robust tracking tools. Karim Karti, CEO of RapidAI, emphasized the significance of the FDA clearance, highlighting how Rapid Aortic exemplifies the company’s mission to deliver deep clinical AI that enhances decision-making across the full continuum of care. He noted that the solution improves efficiency, strengthens care coordination, and ultimately leads to better patient outcomes. Rapid Aortic will be demonstrated at booth #502 during the 2025 VEITH Symposium, offering healthcare professionals a firsthand look at how the technology elevates speed, accuracy, and confidence in managing aortic disease. RapidAI is a global leader in deep clinical AI, trusted by over 2,500 hospitals across more than 100 countries. Backed by more than 700 clinical studies—including research that influenced national stroke treatment guidelines—RapidAI is the most clinically validated AI platform in healthcare. The company continues to advance intelligent imaging solutions that deliver real-world impact at scale.